Participate in Research

​​​Lab research at the bench

We invite our patients to consider participating in the following studies:


Gynecology Studies

Analysis of Inherited Cancer study

Dr Elizabeth Swisher
We are enrolling individuals with known BRCA1 and BRCA2 mutations or mutations in similar cancer causing genes for which pathological blocks of their cancer are available at two different time intervals taken at surgery or from biopsies (i.e. primary cancer and recurrent cancer or two different cancers).

Study coordinator: Kathy Agnew; kagnew@uw.edu or 206-685-7927.

Bacterial Colonization of the Uterus

Dr. Caroline Mitchell
Women who are scheduled to have surgery to remove the uterus are eligible to participate in this study, which is designed to help us understand the normal bacteria in the reproductive tract. All women have bacteria in their vaginas, but we don't know whether these normal bacteria are also present in the uterus. If so, they might play a role in protecting against other infections.

Each woman who enrolls in this study will answer a short questionnaire about her health history and will have samples collected from her uterus after it is removed. We hope that this research will help us understand uterine infections that cause complications like preterm delivery, pelvic inflammatory disease and infertility.

Study coordinator: Evangelyn Nkwopara, evangelc@uw.edu

Evaluation of a Combined Symptom Index & Biomarker Screen for Ovarian Cancer in Patients with a Pelvic mass

Dr. Barbara Goff and Dr. ​Renata Urban
Women 18 and older who have been referred to the Gynecology and Gynecologic ​Oncology clinics at the University of Washington and Seattle Cancer Care Alliance for surgery for a newly diagnosed pelvic mass are invited to participate in a study evaluating symptoms and blood markers prior to surgery. Women who are eligible who wish to participate will fill out a brief survey about recent symptoms they have experienced, as well as have blood drawn prior to and after surgery. This study is voluntary and the blood tests are provided free of charge to study participants.

Study Coordinator: Renata Urban or Barbara Goff MD, 206-543-3559

Top of page

Falloposcopy Study

Dr Elizabeth Swisher
New data suggests that many ovarian cancers actually originate in the lining of the fallopian tube. We are interested in developing a new method to visualize the fallopian tubes in order to develop a novel screening method for ovarian or fallopian tube cancer. Women eligible for this study have a planned preventive surgery to remove the uterus, fallopian tubes and ovaries. At the beginning of the surgery, while the patient is under general anesthesia, we will attempt to visualize the fallopian tubes with a novel ultrathin (1.2 mm diameter) and flexible high definition endoscope.

Study coordinator: Kathy Agnew; kagnew@uw.edu or 206-685-7927

Gynecologic Oncology Tissue Bank

Dr Elizabeth Swisher
Women undergoing gynecological surgery at UWMC are eligible to participate in the Tissue bank. Blood is collected preoperatively and tumor tissue, urine and peritoneal fluid are collected during the time of surgery. All specimens are de-identified and are made available to researchers for their projects upon written request.

Study coordinator: Kathy Agnew; kagnew@uw.edu or 206-685-7927.

Home Human Papilloma Virus (HPV) or Pap Exam (HOPE) Study

Dr. Constance Mao
Women who present to UWMC-Roosevelt or Harborview Medical Center Women’s clinics for routine pap screening are invited to participate. Women ages 21-65 who decide to enroll will be randomized to receive either home HPV or routine Pap exam for their cervical cancer screening.

Each woman who enrolls in this study will answer a short questionnaire about her experience with the screening method used. We hope that this research will allow us to determine if home HPV testing is an acceptable alternative to routine Pap screening.

Study coordinator: Emily Boevers (206)543-3327, eboevers@uw.edu

HPV E6 for Cervical Cancer Screening

Dr. Constance Mao
Women who present for Colposcopy or a LEEP (loop electrocautery excision procedure) to UWMC-Roosevelt or Harborview Women’s Clinics will be invited to participate. Women over age 21 will be asked to allow two cervical specimens for research to be obtained before their scheduled procedure takes place.

We hope this research will allow us to develop a better test for cervical cancer screening that includes looking for HPV E6 proteins.

Study Coordinator: Katie O’connell (206)543-3327, kto1587@uw.edu

Top of page

IGFPB-2 Ovarian Cancer Vaccine Study

Dr. Mary L. Disis and Dr. John B. Liao
We are enrolling individuals with stage 3 or 4 ovarian cancer who have been treated to complete remission with standard therapies to test the safety of a DNA vaccine targeting IGFBP-2 and evaluate its ability to stimulate the immune system.

Study coordinator: Stephanie Parker; sparker7@uw.edu or 206-543-6620.

Top of page

OSS: Ovarian Symptom Study

Dr. Barbara Goff
Women presenting to the primary care clinics at UWMC-Roosevelt are invited to participate in a study evaluating symptoms and ovarian masses. Women 40 and older who wish to participate fill out a survey about the symptoms they have experienced over the past year as well as some baseline health information.

Women with a specific pattern of symptoms that may be associated with ovarian masses or tumors are offered a transvaginal ultrasound and a blood test that can help us to identify ovarian masses and tumors. These studies are provided free of charge for study participants who qualify to have them but are also voluntary.

Study coordinator: Jeannette Kane, 206.598.2878.

Serial Sample after Diagnosis of Ovarian Cancer

Dr Elizabeth Swisher
Patients who have been recently diagnosed with Stage III or IV ovarian, tubal or peritoneal cancer and participated in the Gynecologic Oncology Tissue Bank will be offered enrollment to this study. We collect blood and urine samples every 4 months for the 4 years following their diagnosis in order to test new candidate biomarkers that may one day be useful in early diagnosis or prediction of outcomes.

Study coordinator: Kathy Agnew; kagnew@uw.edu or 206-685-7927

Salpingectomy Registry study

Dr Elizabeth Swisher
This study includes women who have had a salpingectomy (removal of the fallopian tube) performed for the purpose of ovarian cancer prevention. We will collect information from participants by phone and paper interview in order to better understand motivations and sources of information for this surgery. Participants will be followed long-term to determine whether they develop cancer and if they later choose to undergo ovarian removal. We hope to gain information that will allow us to better counsel women about ovarian cancer prevention.

Study coordinator: Kathy Agnew; kagnew@uw.edu or 206-685-7927.

Top of page

Studies of Pregnant Women to Understand Autoimmune Diseases

Dr. J. Lee Nelson, Fred Hutchinson Cancer Research Center
This is a study of how pregnancy affects the immune system. We are interested in the differences between pregnancy in healthy women and pregnancy in women with rheumatoid arthritis.

We are seeking volunteers who have no autoimmune disease as well as those who have rheumatoid arthritis. All volunteers must be pregnant or planning to become pregnant. Primary participants will be asked for blood samples. Blood draws may take place at the Fred Hutchinson Research Center or at a clinic that better suits the participant. We would like to collect blood samples before pregnancy, once during each trimester and at least once after delivery.

Healthy participants will be paid $20 for each blood draw. Along with the blood draws, we would like to obtain a small amount of umbilical cord blood from each participant's baby after delivery. This does not affect the normal process of delivery.

Each participant will fill out a questionnaire about health, family and pregnancy history. Husbands, mothers and previous children will be asked for a cheek swab, a mouth-swish sample or a hair sample in order to collect small amounts of DNA for genetic typing. This information will be compared with results from other families who are participating in the study. For more information about this study, please visit our web site.

Study coordinator: Dawn Stief, 206.667.6850 or 866.648.1917 (toll free) or lnelsonlab@fhcrc.org.

V2 Repository - Understanding Inflammatory and Infectious Vulvovaginal Disorders

Dr. Caroline Mitchell
This study aims to create a repository of clinical information and biologic specimens that will allow research into causes for common but poorly understood vulvar and vaginal complaints such as pain, discharge, itching and burning. Women presenting to clinic with vulvar or vaginal symptoms, or women presenting for a routine annual exam are eligible to enroll.

Women who enroll in this study answer a short questionnaire, and have additional research samples collected during the course of their regular clinical exam.

Study coordinator: Evangelyn Nkwopara, evangelc@uw.edu

Top of page


Maternal-Child Studies

The Infant Immunity Study

Dr. Soren Gantt
Co-investigators: Dr. Hilary Gammill, Dr. Caroline Mitchell
Healthy adult pregnant women and healthy infants can participate in this study. Eligible participants must intend to deliver at the University of Washington Medical Center (UWMC), and take their baby to the Pediatric Care Center at UWMC Roosevelt Clinic. Eligible participants must also plan to follow the recommended vaccine schedule for their baby since this research studies the immune response to the routine vaccine schedule.

Infection is the #1 cause of death in children worldwide. According to the World Health Organization (WHO), it is estimated that 7 million children die annually of infections. The younger a child is, the more likely they are to have a serious infection. For example, even common cold viruses frequently make infants so sick that they have to be hospitalized. We know that a major reason for this is that babies' immune systems do not fight infections as well as those of older children or adults. Vaccinating your baby is a very important way to prevent infections, but unfortunately current vaccines cannot completely protect babies.

Once enrolled, researchers will follow infants in the first year of their life and observe their immune response to the routine childhood vaccines they receive by taking a small sample of blood before each vaccine is given. Researchers will also obtain samples from the cord blood and placenta at birth, as well as collect a blood sample from the mother during the third trimester and during labor and delivery. Researchers will also collect some basic clinical information about the mothers and their baby such as medical history, medications used, infant feeding practices and more.

Study coordinator: Genecelle Delossantos, gen7@uw.edu

Top of page


Multi-Clinical Trials

A number of multi-center clinical trials are available to gynecologic cancer patients which may allow them access to new and promising therapies.

Ovary

Phase II randomized study of weekly Paclitaxel with or without Alisterib, a novel Aurora A Kinase inhibitor, in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer
Dr. Barbara Goff
Study Coordinator: Joelle Machia 206.667.5152

Phase III randomized double-blind study comparing EC145 and Doxil versus Doxil for platinum resistant ovarian, fallopian or primary peritoneal cancer
Dr. Barbara Goff
Study Coordinator: Monica Dherin 206.667.4696

Phase II randomized study of Weekly paclitaxel plus Pazopanib versus weekly Paclitaxel plus placebo for recurrent or persistent ovarian, primary peritoneal or fallopian tube cancer.
Dr. Benjamin Greer
Study Coordinator: Monica Dherin 206.667.4696

Phase III randomized study of Carboplatin plus Paclitaxel (or Gemcitabine) alone or in combination with Bevacizumab followed by maintenance Bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, primary peritoneal and fallopian tube cancer.
Dr. Benjamin Greer
Study Coordinator: Monica Dherin 206.667.4696

Phase II study of Paclitaxel, Carboplatin and Temsirolimus with Temsirolimus maintenance for clear cell ovarian cancer.
Dr. Benjamin Greer
Study Coordinator: Monica Dherin 206.667.4696

Phase III Study of Maintenance chemotherapy comparing 12 Monthly Cycles of Paclitaxel or Opaxio versus no treatment until documented relapse for women with advanced ovarian, primary peritoneal or fallopian tube cancer who achieve a complete response to primary chemotherapy.
Dr. Benjamin Greer
Study Coordinator: Monica Dherin 206.667.4696

Phase III study of Paclitaxel plus Carboplatin versus Paclitaxel plus Ifosfamide for uterine or ovarian carcinosarcoma
Dr. Benjamin Greer
Study Coordinator: Monica Dherin 206.667.4696

Phase I trial of ABT-888 PARP inhibitor in combination with gemcitabine and carboplatin for advanced ovarian and breast cancer.
Dr. Heidi Gray
Study coordinator: Bojana Askovich, 206.667.4696

PET and biomarkers in treatment response in advanced ovarian and primary peritoneal cancers (Stage IIIC-IV Previously untreated patients will have biopsy proven carcinoma and are candidates for neoadjuvant chemotherapy.
Dr. Joseph Rajendran
Study coordinator: Ann Wilson, 206.598.2383

Advanced or recurrent epithelial ovarian cancer SCCA Phase I: MDX-1105 an anti-PDL-1 antibody for selected advanced solid tumors.
Dr. Scott Tykodi
Study coordinator: Bojana Askovich, 206.667.4696

Endometrial

Phase III randomized study of Radiation with concurrent Cisplatin followed by Carboplatin plus Paclitaxel versus Paclitaxel plus Carboplatin for advanced stage endometrial cancer
Dr. Benjamin Greer
Study Coordinator: Monica Dherin 206.667.4696

Phase III randomized study of pelvic radiation therapy versus vaginal cuff brachytherapy followed by paclitaxel plus carboplatin chemotherapy in patients with high risk, early-stage endometrial cancer.
Dr. Benjamin Greer
Study Coordinator: Monica Dherin 206.667.4696

Cervical

Phase II study of PARP inhibitor ABT-888 plus Topotecan for recurrent or persistent cervical cancer
Dr. Benjamin Greer
Study Coordinator: Monica Dherin 206.667.4696

Phase III study randomized study of concurrent chemotherapy and pelvic radiation therapy with or without adjuvant chemotherapy in high-risk patients with early-stage cervical cancer following radical hysterectomy.
Dr. Heidi Gray
Study Coordinator: Monica Dherin 206.667.4696

Top of page